Lumea Adds TreatmentGPS Alpine Path to Pathology Reports

Lumea and TreatmentGPS have integrated Alpine Path into Lumea’s pathology software to add AI-powered, guideline-based treatment guidance directly into reports. The tool is aimed at helping urologists and patients get clearer next-step information at the moment of diagnosis.

Why it matters: - The integration brings treatment guidance into the pathology report itself, reducing the need for clinicians to manually cross-reference findings with NCCN guidelines. - The workflow is designed to save time, improve consistency and give patients a plain-language summary alongside the clinical report. - Lumea and TreatmentGPS are targeting biopsy-related reports for prostate and bladder cancer, including metastatic prostate cancer cases.

What happened: - Lumea and TreatmentGPS announced the Alpine Path integration into Lumea’s software on Sept. 1, 2026. - The integration adds guideline-based treatment guidance directly into the pathology reporting workflow. - When a urologist orders the test, Alpine Path reviews pathology findings and generates a structured clinical summary aligned with current NCCN guidelines. - Lumea CEO James Thackeray said the integration reflects a view that pathology reporting should connect a diagnosis to a clear, guideline-based next step.

The details: - Alpine Path’s summary includes NCCN-based risk stratification, ancillary testing considerations and treatment considerations based on pathology findings. - The report gives providers a concise reference next to the pathologist’s original report. - Alpine Path also produces a patient-friendly version that translates medical terminology into plain language. - The patient version is intended to help patients understand diagnosis, risk category and treatment options. - Alpine Path can be enabled by default for a practice or ordered as an ancillary test after the pathology report. - The product is currently available for biopsy-related pathology reports covering prostate and bladder cancer. - The integration is meant to avoid adding work for the clinical team while delivering a single summary of key findings and recommendations. - TreatmentGPS says physicians and patients need clarity at the moment of diagnosis, not another system to log into.

Between the lines: - The launch shows continued movement toward embedding AI decision support inside existing clinical workflows rather than as a separate tool. - The combination of provider-facing guidance and patient education in one report is designed to standardize how evidence-based recommendations reach both audiences. - Alpine Path was designed by practicing urologists, which signals a product strategy centered on specialty workflow fit rather than generic AI support.

What’s next: - Lumea is inviting practices to book a demo to evaluate Alpine Path inside the pathology report. - TreatmentGPS said Alpine Path is already used and evaluated by leading urology practices across the U.S., including Oregon Urology Institute, Minnesota Urology and Urology Nevada. - Lumea and TreatmentGPS are positioning the integration as a step toward more informed treatment decisions after cancer diagnosis.

The bottom line: - Alpine Path puts AI-generated, guideline-based treatment guidance directly into pathology reports, aiming to speed decisions, improve consistency and make complex findings easier for both providers and patients to understand.

More information is available on Lumea’s website and TreatmentGPS’s website.